Kenneth R. Chapman

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman et al. · New England Journal of Medicine · 2016 · 852 citations · Full text

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Shawn D. Aaron, Katherine L. Vandemheen, Dean Fergusson et al. · PubMed · 2007 · 650 citations

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen et al. · The Lancet · 2015 · 494 citations

Lung Density, Pulmonary Pharmacology, Placebo-controlled Trial +4

Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide.

Philip E. Silkoff, Patricia McClean, Arthur S. Slutsky et al. · American Journal of Respiratory and Critical Care Medicine · 1997 · 469 citations

Asthma, No Excretion, Lung Deposition +14

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

Nicola A. Hanania, Phillip E. Korenblat, Kenneth R. Chapman et al. · The Lancet Respiratory Medicine · 2016 · 463 citations

Asthma, Rheumatology, Allergy +10